Outcome of transplantation for myelofibrosis. - Wikidata - awgldk - TriplyDB

Outcome of transplantation for myelofibrosis.

Outcome of transplantation for myelofibrosis.

http://www.wikidata.org/entity/Q34015474

about

Emerging treatment options for myelofibrosis: focus on pacritinib Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms Guidelines for the management of myeloproliferative neoplasms Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups Allogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitors Advances in the management of myelofibrosis The evolving treatment paradigm in myelofibrosis Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients.Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis.Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib Emerging drugs for myelofibrosis.Managing patients with myelofibrosis and low platelet counts.Allogeneic transplantation for primary myelofibrosis with BM, peripheral blood or umbilical cord blood: an analysis of the JSHCT Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.Role of hematopoietic stem cell transplantation in patients with myeloproliferative disease.Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia.Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age.Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation.How to manage the transplant question in myelofibrosis.Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase.Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients.Philadelphia-negative chronic myeloproliferative neoplasms Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib.One thousand patients with primary myelofibrosis: the mayo clinic experience.New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape.Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.Anti-thymocyte globulin (thymoglobulin), tacrolimus, and sirolimus as acute graft-versus-host disease prophylaxis for unrelated hematopoietic stem cell transplantation.Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research.Early Improvement in Marrow Fibrosis Following Haploidentical Stem Cell Transplantation for a Patient with Myelodysplastic Syndrome with Bone Marrow Fibrosis.Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes.Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management.Allogeneic stem cell transplantation for myelofibrosis in 2012.Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors.

P2860

Q26745939-78CC752E-66A1-4143-BC56-16B2EB0191F1 Q26766319-4D60948D-6B4F-41D5-BF2D-EE97F501CD28 Q26778326-ED642A41-3985-4311-B88A-2FD50F9A6878 Q26786893-8D7E3FFA-568F-47D5-AA15-DC6279843A72 Q26863610-5B0126F5-680D-4E46-857F-30AE72D33C90 Q27008072-426D70CA-7CB5-470A-8B0D-796B5A62E657 Q27021968-3A6AD419-5B60-4D3F-A65E-2E9FDC63B194 Q33392291-1517CAF7-AD17-412E-9883-F0566C6160E9 Q33393151-2D0292A4-BEDB-4D46-B529-ACC9A9704D29 Q33400683-49127D44-FD09-47D3-A7CB-610D0CF197FA Q33402522-0EA5B13E-12CE-4A27-A8A3-C84E7276FFF5 Q33404574-220F64AF-8CDC-47EA-9313-842027355A80 Q33432406-B4F838BE-04B0-41B1-98E5-0A27DC466580 Q33556843-FA36B63B-D03F-4133-A4A6-421D150E6F20 Q33843390-947EC299-2892-4C0E-B014-CC37D0079DFA Q34047897-0207DD59-B9CB-4C8F-9F93-F8D521EAA929 Q34165935-B12A2831-0D8B-4064-B6E7-9E7E17169EB9 Q34302770-9F064C86-6828-427B-949A-FF670ED46C4A Q34625390-662D69DF-DC7A-457F-A19E-977154D8BBA1 Q35188877-0353AB3F-D461-4EC9-AF47-B39643048C16 Q35608022-84025DA1-C137-42A7-974F-4EAAFA0C10C9 Q35735663-C11476E0-804D-4BAD-B4AD-A57A19A4EAA6 Q35849342-74CFD3E1-F6E7-4775-869F-FF09699F4194 Q35865676-A64FD8FA-2649-433F-B920-4F762D1263F9 Q35988523-4C6E0CD4-6F76-4782-B40E-2CDB6DA61BB4 Q36166896-A69F4481-E088-4222-9DE3-E5737CA7F1DB Q36283143-3CE52779-E36E-4BBB-B485-179B05EBE3CB Q36305314-C6F84C8F-0441-4770-BB19-E9FAE0B60500 Q36512816-006F06D7-13EB-40F2-9B20-7100AABF6B7B Q36782943-FB8D3795-4B04-484A-A269-CB30FCB96372 Q37163590-1EB37A63-5181-4E72-BD1E-58F457640883 Q37184046-D7433011-8735-44B6-BD57-85082F91A31F Q37272164-BBB24C53-E5AA-468A-A79F-9D0E786BF979 Q37457111-8FBA8EDE-581A-4293-AFEA-A8239AB5B3EE Q37521161-25F52C28-2873-495D-8F8A-5581E5F5247D Q37548944-B55D6E34-0995-45CE-BD2A-C9AEFA2524A8 Q37877727-18834AE3-2AB5-4D7A-90EC-94F7F6D75061 Q37956603-4A943A11-9455-47D6-B3FA-A4F5DDFCAF40 Q37998567-6086DAFF-4691-4364-9652-1E60B5B5DACD Q38018908-C25C80C0-16BA-4316-A2BB-1DB2686DF991

P2860

Outcome of transplantation for myelofibrosis.

http://www.wikidata.org/entity/Q34015474

description

2009 nî lūn-bûn

@nan

2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Outcome of transplantation for myelofibrosis.

@ast

Outcome of transplantation for myelofibrosis.

@en

Outcome of transplantation for myelofibrosis.

@nl

type

label

Outcome of transplantation for myelofibrosis.

@ast

Outcome of transplantation for myelofibrosis.

@en

Outcome of transplantation for myelofibrosis.

@nl

prefLabel

Outcome of transplantation for myelofibrosis.

@ast

Outcome of transplantation for myelofibrosis.

@en

Outcome of transplantation for myelofibrosis.

@nl

P1433

Q34015474-767E4F5A-956B-4C11-A602-A4C434F3E103

P1476

Q34015474-BD9488E9-D5F4-43CC-A6FB-CEF33EF14AA7

P2093

Q34015474-06A25991-F9B4-4E48-9456-67C525169771

Q34015474-0BCA177B-D323-43D0-A013-33B18686FC62

Q34015474-0EED6CF7-A6F6-4B26-84AF-75050656B5F9

Q34015474-253C8DED-A382-4D2D-AAF3-BD251ED0CD06

Q34015474-2834D086-66A6-4C84-B678-96B72D718670

Q34015474-293B009A-6411-4F62-8323-01564A230DC3

Q34015474-679EFBC6-9C0B-4905-831B-1693A0921E72

Q34015474-6A55B81D-F022-49FD-87A9-3984690B3673

Q34015474-6D636B62-2EA2-4440-83F3-2A2CCA0A3BAC

Q34015474-74BE24AD-47D7-4A22-B072-FC3469D1133D

P2860

Q34015474-0E9AA71E-3CC6-42A6-A138-6B7C9CBE66C3

Q34015474-1703C39F-03D2-495D-B6AD-59F1ABF1E072

Q34015474-27D4247A-F790-4534-9076-9BA084E36BB3

Q34015474-353D5A37-1795-4B3A-8750-2E3F9FC9D445

Q34015474-3756C899-4712-4911-BA6E-F108BE2EEBA7

Q34015474-3953E420-3CCC-4111-BD66-5CA29E7385DC

Q34015474-43B2AB9E-2FDE-4481-A9FF-DA8FE58DEBE1

Q34015474-46DD3F9E-3086-4F33-A4AE-1B2A22BC80F2

Q34015474-4CA6EFD6-A265-40BB-912D-4E8C7CA1F82D

Q34015474-55680E94-7B4C-4060-8460-C947D1DCB77F

P304

Q34015474-C855D700-301F-4BD5-92F1-BEE7C7A2726D

P31

Q34015474-694540A6-ACCB-42A7-B505-F21CE9C4DF11

P356

Q34015474-871D0322-FB7E-4CEB-B809-51AD2D9DD0E1

P433

Q34015474-FEAC6C5A-412B-42D6-9AE2-9FF2BCAE092B

P478

Q34015474-CB4966FA-F0C5-4ED5-A7D7-7829C98480C2

P50

Q34015474-4194B330-1B0C-4F64-A48B-3E3A040BB14F

P577

Q34015474-D7D9A254-2C70-40BC-9A24-4DB519571BF8

P5875

Q34015474-361336CF-C538-4F22-B433-7276BB7E45E5

P698

Q34015474-3D71F61E-61CF-4A7B-94B9-C9DE67677630

P932

Q34015474-B681A5F2-D803-4B0C-9CA4-66E6B6E01093

P356

J.BBMT.2009.10.025

P1433

Biology of Blood and Marrow Transplantation

P1476

Outcome of transplantation for myelofibrosis.

@en

P2093

Asad Bashey

http://www.w3.org/2001/XMLSchema#string

Brian J Bolwell

http://www.w3.org/2001/XMLSchema#string

David I Marks

http://www.w3.org/2001/XMLSchema#string

Francisco Cervantes

http://www.w3.org/2001/XMLSchema#string

Gary Schiller

http://www.w3.org/2001/XMLSchema#string

Harry C Schouten

http://www.w3.org/2001/XMLSchema#string

Karen K Ballen

http://www.w3.org/2001/XMLSchema#string

Kathleen A Sobocinski

http://www.w3.org/2001/XMLSchema#string

Mark R Litzow

http://www.w3.org/2001/XMLSchema#string

Mary M Horowitz

http://www.w3.org/2001/XMLSchema#string

P2860

Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation.

Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients.

A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia.

Modern management of myelofibrosis.

The role of interferon-alpha in the treatment of idiopathic myelofibrosis.

Choosing between stem cell therapy and drugs in myelofibrosis.

Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research

The forgotten myeloproliferative disorder: myeloid metaplasia.

New approaches in the treatment of myelofibrosis.

Allogeneic hematopoietic stem cell transplantation for myelofibrosis.

P304

358-367

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BBMT.2009.10.025

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Robert Peter Gale

P577

2009-10-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38058208

http://www.w3.org/2001/XMLSchema#string

P698

19879949

http://www.w3.org/2001/XMLSchema#string

P932

2908949

http://www.w3.org/2001/XMLSchema#string